Alvaiz (Eltrombopag Choline) Patent Expiration, LOE Window & CMS Spending

Alvaiz (Eltrombopag Choline) by Teva Pharmaceuticals: FDA Orange Book core substance LOE 2038-11-05, 0 AB generics, $10.1M 2024 CMS Part D & Medicaid spend, and $18,688 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTeva Pharmaceuticals
FDA Application & PathwayN216774 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-11-05
Last Listed Patent or Exclusivity Date2038-11-05
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$10.1M
2024 Medicare Part D Spend$8.2M
2024 Medicaid Spend$1.9M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($18,688 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.